Download PDF
Horm Metab Res 2011; 43(09): 607-613
DOI: 10.1055/s-0031-1284355
Original Basic
Georg Thieme Verlag KG Stuttgart · New York

Enhanced Oxidative Stress and Platelet Activation Combined with Reduced Antioxidant Capacity in Obese Prepubertal and Adolescent Girls with Full or Partial Metabolic Syndrome

I. Karamouzis
1   Division of Endocrinology, Diabetology and Metabolism, First Department of Pediatrics, Athens University Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece
,
P. Pervanidou
1   Division of Endocrinology, Diabetology and Metabolism, First Department of Pediatrics, Athens University Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece
,
R. Berardelli
2   Division of Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University of Turin, Italy
,
S. Iliadis
3   Laboratory of Biological Chemistry, Faculty of Medicine, Aristotle University of Thessaloniki, Greece
,
I. Papassotiriou
4   Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hospital, Athens, Greece
,
M. Karamouzis
3   Laboratory of Biological Chemistry, Faculty of Medicine, Aristotle University of Thessaloniki, Greece
,
G. P. Chrousos
1   Division of Endocrinology, Diabetology and Metabolism, First Department of Pediatrics, Athens University Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece
,
C. Kanaka-Gantenbein
1   Division of Endocrinology, Diabetology and Metabolism, First Department of Pediatrics, Athens University Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece
› Author Affiliations
Further Information

Publication History

received 11 January 2011

accepted 30 June 2011

Publication Date:
05 August 2011 (online)

Also available at
    Permissions and Reprints

Abstract

In adults, obesity is a main factor implicated in increased oxidative stress (OS), platelet activation (PA) and impaired antioxidant status (AS), all predisposing factors for cardiovascular disease leading to increased morbidity and mortality. Furthermore, the metabolic syndrome (MetS) is an important cardiovascular risk factor, which progressively develops and may already be present during late childhood or adolescence. However, scarce data exist on oxidative-antioxidant balance and PA in childhood and adolescence in the presence of partial (PMetS) or full MetS. The aim of the study was to evaluate OS, PA, and AS in prepubertal and adolescent obese girls with partial or full MetS. 96 girls with a clinical and metabolic evaluation for obesity and 44 healthy normal-weight sex- and age-matched girls were studied. IDF-adopted criteria were used to define full and partial MetS and the patient population was divided into 4 groups: the first comprised 31 pre-pubertal girls with PMetS (PR-PMetS), the second 37 adolescents with PMetS (AD-PMetS), the third 10 prepubertal girls with full MetS (PR-MetS), and the fourth 18 adolescents with full MetS (AD-MetS). The OS was evaluated by measuring plasma 15-F2t-Isoprostane levels (15-F2t-IsoP) and protein carbonyls, PA by thromboxane B2 levels (TXB2), and AS by serum vitamin E and plasma total antioxidant capacity (TAC) levels. 15-F2t-IsoP, protein carbonyls, and TXB2 levels were significantly gradually amplified, and vitamin E and TAC reduced, and significantly correlated with obesity from childhood to adolescence and from partial to full MetS. This study demonstrates the loss of the normal homeostatic balance between oxidant-antioxidant state in obese children and adolescents with manifestations of partial and full MetS.

Key words

antioxidant state - isoprostane - thromboxane - pediatric obesity - carbonyl proteins
 

  • References

  • 1 Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006; 119 (Suppl. 05) S3-S9
    PubMedGoogle Scholar
  • 2 Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
    CrossrefPubMedGoogle Scholar
  • 3 Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716
    CrossrefPubMedGoogle Scholar
  • 4 Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419
    CrossrefPubMedGoogle Scholar
  • 5 Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-1257
    CrossrefPubMedGoogle Scholar
  • 6 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
    CrossrefPubMedGoogle Scholar
  • 7 Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443
    CrossrefPubMedGoogle Scholar
  • 8 Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480
    CrossrefPubMedGoogle Scholar
  • 9 World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation part 1: diagnosis and classification of diabetes mellitus, Geneva, 1999 59
    PubMedGoogle Scholar
  • 10 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 (9468) 1415-1428
    CrossrefPubMedGoogle Scholar
  • 11 World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894 (i–xii) 1-253
    PubMedGoogle Scholar
  • 12 Lobstein T, Baur L, Uauy R. IASO International Obesity Task Force. Obesity in children and young people: a crisis in public heath. Obes Rev 2004; 5 (Suppl. 01) 4-104
    CrossrefPubMedGoogle Scholar
  • 13 Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006; 1: 11-25
    CrossrefPubMedGoogle Scholar
  • 14 Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005; 25: 553-569
    CrossrefPubMedGoogle Scholar
  • 15 Knight JA. Free Radicals: their presence in biological system. In: Free Radicals, Antioxidants, Aging, and Disease. Washington: AACC Press; 1999: 21-43
    Google Scholar
  • 16 Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84
    CrossrefPubMedGoogle Scholar
  • 17 Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005; 14: 760-764
    CrossrefPubMedGoogle Scholar
  • 18 Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 2008; 28: 397-404
    CrossrefPubMedGoogle Scholar
  • 19 Karamouzis I, Grekas D, Karamouzis M, Triantos A, Vasileva-Staikova S, Kovachev D, Dimitriadou A. Enhanced oxidative stress with gradient between plasma and muscle interstitial fluid in patients with end stage renal failure on hemodialysis. Hormones (Athens) 2008; 7: 62-69
    PubMedGoogle Scholar
  • 20 Karamouzis I, Grekas D, Karamouzis M, Kallaras K, Stergiou-Michailidou V, Kouidi E, Deligiannis A, Vavatsi-Christaki N. Physical training in patients on hemodialysis has a beneficial effect on the levels of eicosanoid hormone-like substances. Hormones (Athens) 2009; 8: 129-137
    PubMedGoogle Scholar
  • 21 Giannini C, De Giorgis T, Scarinci A, Cataldo I, Marcovecchio ML, Chiarelli F, Mohn A. Increased carotid intima-media thickness in pre-pubertal children with constitutional leanness and severe obesity: the speculative role of insulin sensitivity, oxidant status, and chronic inflammation. Eur J Endocrinol 2009; 161: 73-80
    CrossrefPubMedGoogle Scholar
  • 22 Kaufman CL, Kaiser DR, Steinberger J, Kelly AS, Dengel DR. Relationships of cardiac autonomic function with metabolic abnormalities in childhood obesity. Obesity 2007; 15: 1164-1171
    CrossrefPubMedGoogle Scholar
  • 23 Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, Maruyama N, Kitagawa N, Tanaka T, Hori Y, Nakatani K, Yano Y, Adachi Y. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003; 88: 4673-4676
    CrossrefPubMedGoogle Scholar
  • 24 Kelly AS, Steinberger J, Kaiser DR, Olson TP, Bank AJ, Dengel DR. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr 2006; 1: 248-252
    CrossrefPubMedGoogle Scholar
  • 25 Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538
    CrossrefPubMedGoogle Scholar
  • 26 Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014
    CrossrefPubMedGoogle Scholar
  • 27 Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513
    CrossrefPubMedGoogle Scholar
  • 28 Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279-286
    PubMedGoogle Scholar
  • 29 Morrow JD, Hill E, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in human by non-cycloxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387
    CrossrefPubMedGoogle Scholar
  • 30 Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 24441-24444
    CrossrefPubMedGoogle Scholar
  • 31 Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23: 360-366
    CrossrefPubMedGoogle Scholar
  • 32 Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem 1995; 270: 9800-9808
    CrossrefPubMedGoogle Scholar
  • 33 Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. The isoprostanes: a perspective. Prostaglandins 1997; 54: 823-851
    CrossrefPubMedGoogle Scholar
  • 34 Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: Markers and mediators of oxidative stress. FASEB J 2004; 8: 1791-1800
    PubMedGoogle Scholar
  • 35 Stadtman ER, Oliver CN. Metal-catalyzed oxidation of protein. Physiological consequences. J Biol Chem 1991; 266: 2005-2008
    PubMedGoogle Scholar
  • 36 Nakahata N. Thromboxane A2: Physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118: 18-35
    CrossrefPubMedGoogle Scholar
  • 37 Morrow JD, Awad JA, Wu A, Zackert WE, Daniel VC, Roberts LJ. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem 1996; 271: 23185-23190
    CrossrefPubMedGoogle Scholar
  • 38 Van Kraaij DJ, Hovestad-Witterland AHI, de Metz M, Vollaard EJ. A comparison of the effects of nabumetone vs. meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol 2002; 53: 644-647
    CrossrefPubMedGoogle Scholar
  • 39 Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cadiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001; 134: 1385-1392
    CrossrefPubMedGoogle Scholar
  • 40 Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V. High glucose causes upregulation of cycloxygenase-2 and alters prostanoid profile in human endothelial cells. Circulation 2003; 107: 1017-1023
    CrossrefPubMedGoogle Scholar
  • 41 Dogné JM, Hanson J, Pratico D. Thromboxane prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005; 26: 639-644
    CrossrefPubMedGoogle Scholar
  • 42 Mohn A, Catino M, Capanna R, Giannini C, Marcovecchio M, Chiarelli F. Increased oxidative stress in prepubertal severely obese children: effect of a dietary restriction-weight loss program. J Clin Endocrinol Metab 2005; 90: 2653-2658
    CrossrefPubMedGoogle Scholar
  • 43 Freedman JE, Farhat JH, Loscalzo J, Keaney Jr JF. Alfa-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996; 94: 2434-2440
    CrossrefPubMedGoogle Scholar
  • 44 Koh KK, Oh PC, Quon MJ. Does reversal of oxidative stress and inflammation provide vascular protection?. Cardiovasc Res 2009; 81: 649-659
    PubMedGoogle Scholar
  • 45 Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995; 15: 190-198
    CrossrefPubMedGoogle Scholar
  • 46 Miller NJ, Rice-Evans C. Factors influencing the antioxidant activity determined by the ABTS+ radical cation assay. Free Rad 1997; 26: 195-199
    PubMedGoogle Scholar
  • 47 Nourooz-Zadeh J, Ziegler D, Sohr C, Betteridge JD, Knight J, Hothersall J. The use of Pholasin as a probe for the determination of plasma total antioxidant capacity. Clin Biochem 2006; 39: 55-61
    CrossrefPubMedGoogle Scholar
  • 48 Tinahones FJ, Murri-Pierri M, Garrido-Sánchez L, García-Almeida JM, García-Serrano S, García-Arnés J, García-Fuentes E. Oxidative stress in severely obese persons is greater in those with insulin resistance. Obesity 2009; 17: 240-246
    CrossrefPubMedGoogle Scholar
  • 49 Chiotis D, Krikos X, Tsiftis G, Hatzisymeaon M, Maniati-Christidi M, Dacou-Voutetakis C. Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0–18years, living in the Athens area. Ann Clin Paediatr Univ Atheniensis 2004; 51: 139-154
    PubMedGoogle Scholar
  • 50 Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establising a standard definition for child overweight and obesity worldwide: international survey. BMI 2000; 320 (7244) 1240-1243
    PubMedGoogle Scholar
  • 51 Tanner JM. Growth at adolescence. 2nd ed. Oxford: Blackwell Scientific Publications; 1962
    Google Scholar
  • 52 Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. Consensus Group. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306
    CrossrefPubMedGoogle Scholar
  • 53 Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified protein. Method Enzymol 1994; 233: 346-357
    PubMedGoogle Scholar
  • 54 Arnaud J, Fortis I, Blachier S, Kia D, Favier A. Simultaneous determination of retinol, alpha-tocopherol and beta-carotene in serum by isocratic high-performance liquid chromatographyination of retinol, alpha-tocopherol and beta-carotene in serum by isocratic high-performance liquid chromatography. J Chromatogr 1991; 572: 103-116
    CrossrefPubMedGoogle Scholar
  • 55 Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002; 26: 754-764
    CrossrefPubMedGoogle Scholar
  • 56 Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50: 159-165
    CrossrefPubMedGoogle Scholar
  • 57 Giannini C, De Giorgis T, Scarinci A, Ciampani M, Marcovecchio ML, Chiarelli F, Mohn A. Obese related effects of inflammatory markers and insulin resistance on increased carotid intima media thickness in pre-pubertal children. Atherosclerosis 2008; 197: 448-456
    CrossrefPubMedGoogle Scholar
  • 58 Codoñer-Franch P, Tavárez-Alonso S, Murria-Estal R, Tortajada-Girbés M, Simó-Jordá R, Alonso-Iglesias E. Elevated advanced oxidation protein products (AOPPs) indicate metabolic risk in severely obese children. Nutr Metab Cardiovasc Dis 2010; Aug: 12 [Epub ahead of print]
    PubMedGoogle Scholar
  • 59 Strauss RS. Comparison of serum concentrations of alpha tocopherol and beta-carotene in a cross-sectional sample of obese and non obese children (NHANES III). National Health and Nutrition Examination survey. J Pediatr 1999; 134: 160-165
    CrossrefPubMedGoogle Scholar
  • 60 Puchau B, Ochoa MC, Zulet MA, Marti A, Martínez JA, Members G. Dietary total antioxidant capacity and obesity in children and adolescents. Int J Food Sci Nutr 2010; 61: 713-721
    CrossrefPubMedGoogle Scholar
  • 61 Morinobu T, Muzata T, Takaya R, Tamai H. Nutritional Status of beta-carotene, alpha-tocopherol and renitol in obese children. Int J Vitam Nutr Res 2002; 72: 119-123
    CrossrefPubMedGoogle Scholar
  • 62 Codoner-Franch P, Boix-Garcia L, Simó-Jordá R, Del Castillo-Villaescusa C, Maset-Maldonado J, Valls-Belles V. Is obesity associated with oxidative stress in children?. Int J Pediatr Obes 2010; 5: 56-63
    CrossrefPubMedGoogle Scholar